Miragene Inc. (the "Company") was formed in November 2000, as result of the acquisition of Miragen, Inc. and its patented technology. The Company recognized a unique opportunity to further develop the technology by converting it onto a state-of-the-art protein microarray platform. The Company owns two issued patents and has since filed ten new provisional patent applications. The original patents were the result of more than ten years of research in the field of autoimmune disease at Scripps Research Institute, Salk Research Institute and Cold Spring Harbor Laboratory. The new patents are based on protein microarray technology and include the chips, chemistries and detection systems developed by Miragene since it was established.
MANAGEMENT TEAM
Michael T. O誰eill, B.A. (Physics) President/CEO has 30 years experience in the Life Sciences and Diagnostic Markets. Mr. O誰eill was formerly the Senior VP W/W Operations at Beckman Coulter and responsible for $1 billion in revenues. Mr. O誰eill serves on the board of Newport Corporation.
Mark Benedict, Ph.D. (Biochem) J.D., Licensing and Patent Attorney, Knobbe, Martens, Olson & Bear, LLP. Dr. Benedict was formerly a professor of Biology and Pediatrics at Syracuse Univ.
Stewart Lebrun, B.A., Ph.D., (Biochem) Director of Research & Development, Assistant Professor, Department of Community & Environmental Medicine, University of California, Irvine.
Melanie McCaffery, B.A., MBA. CPA., Financial Controller, formerly partner at Coopers & Lybrand, Newport Beach and Los Angeles offices.
BOARD OF DIRECTORS
Thomas C. Cesario, B.A. M.D., M.A.C.P. Dean of the College of Medicine, University of California, Irvine. Orange County Physician of the Year, 2001. Residency at Harvard.
Mark A. Cole, B.Sc., Ph.D., (Path) Dr. Cole was a founding officer at Biopsys Medical, Inc. and Vice President of Medical Affairs. Johnson & Johnson acquired the Company for $315M.
Theodore S. Halaby, AB., LLB., Founder and Managing Partner, Halaby & Associates, Denver, CO. Mr. Halaby is the Chairman of the State Republican Committee of Colorado.
Michael T. O誰eill, B.A. (Physics) President/CEO has 30 years experience in the Life Sciences and Diagnostic Markets. Mr. O誰eill was formerly the Senior VP W/W Operations at Beckman Coulter.
John A. Osth, B.S. M.S. MBA., President/CEO, QuantumCor, Inc. formerly President of the Immunotherapy Division, Baxter Healthcare Corporation. Formerly at Abbott Laboratories.
SCIENTIFIC ADVISORY BOARD
Sudhir Gupta, M.D., Ph.D., M.A.C.P. Professor of Medicine, Pathology & Molecular Genetics, Chief, Division of Basic & Clinical Immunology, University of California, Irvine.
Calvin S. McLaughlin, B.A. Ph.D., MIT. Professor of Biological Chemistry & Environmental Medicine, formerly Director of Cancer Research Institute, University of California, Irvine.
Minnie McMillan, B.Sc. D.Phil., Oxford. Professor of Molecular Microbiology, Immunology and Neurology, Keck School of Medicine, Unversity of Southern California, Los Angeles.
